Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Conversely, if FTO gene variants suggest increased hunger drive, a higher dose of semaglutide or an alternative agent might be necessary
Glucose- and bile acid-stimulated secretion of gut hormones in the isolated perfused intestine is not impaired in diet-induced obese mice
Joseph Burrascano, Jr., for patients who have chronic or late-stage Lyme, the worst reaction is typically around the fourth week of treatment, very similar to serum sickness where one will have a reduction in white blood cells (leucopenia) and an increase in liver enzymes
[6] Coskun T , Sloop K W , Loghin C ,et al
